A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study.
CONCLUSIONS: Our data demonstrate that MG and US have similar accuracy with regard to tumour size estimation. US assessment showed the highest sensitivity in determining tumour size, followed by MG and CE. However, MG demonstrated a significant advantage for estimating the real tumour size for pT2 tumours compared to US or CE. PMID: 29204896 [PubMed - as supplied by publisher]
ConclusionCHEK2*1100delC is associated with an increased risk of both female and male breast cancer.
No abstract available
CONCLUSIONS Doctors' empathy abilities affected breast cancer patients' NK subset through their stigma and self-efficacy. The mental health of male breast cancer patients need more attention and empathy education needs to be improved. PMID: 29891832 [PubMed - in process]
We examined the microenvironment of archival and contemporary cohorts of MBC, diagnosed 1940–1970 and 1998–2006, respectively, with two cohorts of, archival and contemporary gynaecomastia, diagnosed 1940–1979 and 1996–2011, respectively, serving as controls. We quantified adipocytes, crown-like structures (CLS) and the presence of CD8, α smooth muscle actin (αSMA) and CD68+ macrophages in both cohorts, and determined how these affected survival, in the contemporary MBC cohort. In both MBC cohorts, mean adipocyte diameter was larger in the distant stroma compared with stroma close to the ...
Conclusion This is the first case report of a metastasis of any kind on ACP. Metastasis should be included as a part of the differential diagnosis of lesions of the anterior clinoid. Extradural clinoidectomy is a safe and effective method in the treatment of these tumors. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | open access Full text
CONCLUSIONS Marital status was an important prognostic factor for survival in patients with HR positive MBC. Unmarried patients are at greater risk of death compared with married groups. The survival benefit for married patients remained even after adjustment, which indicates the importance of spousal support in MBC. PMID: 29795054 [PubMed - in process]
Oral and maxillofacial metastatic tumors are uncommon, with the breast, prostate, lung and kidney representing the most common primary sites. Less than 1% of all breast cancers occur in male patients, and to date, only eight cases of metastatic breast adenocarcinoma to the oral and maxillofacial region in a male patient have been reported in the literature. An 88-year-old male with previous history of a successfully treated primary breast adenocarcinoma 12 years earlier was referred for evaluation of an oral swelling lasting 6 months.
Madam — In the retrospective analysis published by Wan et al. , the actuarial median survival time from Kaplan–Meier estimations in 161 male breast cancer patients from a single institution was 19.9 years (95% confidence interval 11.2–25.4).
AbstractX chromosome gain has been previously described in male breast cancer (MBC). Androgen receptor (AR) gene is located on X chromosome. The aim of this study was to investigate the role of the X chromosome gain in the development of MBC and its relation with AR gene copy number and expression.The X chromosome status was assessed in 66 cases of male invasive and in situ duct breast carcinoma, in 34 cases of gynecomastia associated with cancer, and in 11 cases of tumor-free gynecomastia. Cases were tested by fluorescence in situ hybridization (FISH) to assess the X chromosome status and AR amplification. AR expression w...
Conclusions: FES and FDG uptake in multiple lesions from ER+ male breast cancer patients did not differ from female breast cancer. Response and survival are also similar in male and female breast cancer patients in our study. Male breast cancer patients are appropriate for inclusion in imaging and clinical trials of endocrine and molecularly targeted therapies which are synergistic with endocrine therapy. Research Support: P01CA42045, R01CA72064, R01CA148131, DOD W81XWH-04-01-0675